Home › Immune System and Disorders › Texas › Dallas
Immune System and Disorders clinical trials in Dallas, TX
4 studies for Immune System and Disorders are looking for participants at sites in and around Dallas (within about 30 miles). Open a study to see who can join and how to contact the study team.
Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
RecruitingPhase 1/2
- Baylor University Medical Center, Dallas
Open-label Extension Study of Zigakibart in Adults With IgA Nephropathy.
RecruitingPhase 3
- Dallas Renal Group, Dallas
- Dallas Renal Group, Dallas
A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris (RESET-PV)
RecruitingPhase 1/2
- UT Southwestern Medical Center, Dept. of Dermatology, Dallas
A Study to Evaluate Vimseltinib in Adults With Active Chronic Graft-Versus-Host Disease (cGVHD)
RecruitingPhase 2
- UT Southwestern Medical Center, Dallas
About Immune System and Disorders
Your immune system is made up of cells, tissues, and organs that fight infections and diseases. Learn how it works, and about diseases of the immune system.
More about Immune System and Disorders on MedlinePlus
Immune System and Disorders trials in other cities
- Washington, DC13 studies
- New York City, NY12 studies
- Philadelphia, PA10 studies
- Boston, MA10 studies
- Houston, TX9 studies
- Portland, OR9 studies
- Atlanta, GA9 studies
- Los Angeles, CA8 studies
- Cleveland, OH8 studies
- Chicago, IL8 studies
- Milwaukee, WI6 studies
- Cedar Rapids, IA6 studies
Other studies in Dallas
- Breast Cancer54 studies
- Non-Small Cell Lung Cancer52 studies
- Heart Failure42 studies
- Metastatic Cancer42 studies
- Cancer (all types)38 studies
- Prostate Cancer36 studies
- Colorectal Cancer33 studies
- Obesity31 studies
- Ovarian Cancer28 studies
- Bladder Cancer27 studies
- Lung Cancer27 studies
- Endometrial Cancer25 studies
From ClinicalTrials.gov, data retrieved Oct 1, 2026. Each study sets its own eligibility; the study team decides who can join.